Literature DB >> 4402080

Pharmacologic studies of indoramin in man.

R B Royds, D J Coltart, J D Lockhart.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4402080     DOI: 10.1002/cpt1972133380

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  8 in total

1.  Clinical evaluation of indoramin, a new antihypertensive agent.

Authors:  P J Lewis; C F George; C T Dollery
Journal:  Eur J Clin Pharmacol       Date:  1973-12       Impact factor: 2.953

2.  Some clinical pharmacological studies with indoramin, with observations on its therapeutic usefulness.

Authors:  C de White; R B Royds; P Turner
Journal:  Postgrad Med J       Date:  1974-12       Impact factor: 2.401

3.  Prolonged effect of antihypertensive agents.

Authors:  C de B White; R B Royds; P Turner
Journal:  Br Med J       Date:  1974-07-06

4.  Pharmacokinetics of indoramin in man.

Authors:  G H Draffan; P J Lewis; J L Firmin; T W Jordan; C T Dollery
Journal:  Br J Clin Pharmacol       Date:  1976-06       Impact factor: 4.335

5.  Cardiovascular effects of indoramin in man--a dose ranging study.

Authors:  D P Nicholls; D W Harron; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1983-01       Impact factor: 4.335

6.  Prevention of exercise-induced asthma by indoramin.

Authors:  S Bianco; J P Griffin; P L Kamburoff; F J Prime
Journal:  Br Med J       Date:  1974-10-05

7.  Evaluation of indoramin added to oxprenolol and bendrofluazide as a third agent in severe hypertension.

Authors:  A J Marshall; M A Kettle; D W Barritt
Journal:  Br J Clin Pharmacol       Date:  1980-09       Impact factor: 4.335

8.  Effect of acute and chronic oral administration of alfuzosin on baroreflex function and tremor in man.

Authors:  A H Deering; J G Riddell; D W Harron; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1988-04       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.